CT-721 manufacturers
- CT-721
-
- $1970.00
-
2026-07-27
- CAS:1388710-60-8
- Purity:
- Supply Ability: 10g
- CT-721
-
- $1970.00
-
2026-07-27
- CAS:1388710-60-8
- Purity:
- Supply Ability: 10g
- CT-721
-
- $1970.00
-
2025-08-22
- CAS:1388710-60-8
- Purity:
- Supply Ability: 10g
|
| Product Name: | CT-721 | | Synonyms: | CT-721;CT721,CT 721;1H-Indene-5-carboxamide, N-[3-[2-(6-chloroimidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methylphenyl]-2,3-dihydro-1-(4-methyl-1-piperazinyl)-, (1S)- | | CAS: | 1388710-60-8 | | MF: | C30H29ClN6O | | MW: | 525.04 | | EINECS: | | | Product Categories: | | | Mol File: | 1388710-60-8.mol |  |
| | CT-721 Chemical Properties |
| density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 13.36±0.70(Predicted) |
| | CT-721 Usage And Synthesis |
| Uses | CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities[1]. CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | References | [1] Sun Y, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer. 2017 Aug 23;8(14):2774-2784. DOI:10.7150/jca.18731 |
| | CT-721 Preparation Products And Raw materials |
|